Canada Pension Plan Investment Board Purchases 81,192 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• The Canada Pension Plan Investment Board increased its stake in Cellebrite DI Ltd. by 100.9% in the first quarter, owning approximately 0.07% of the company valued at $3.14 million.
• Cellebrite DI reported Q2 earnings of $0.12 per share, surpassing estimates, with a revenue of $113.28 million, reflecting an 18.4% year-over-year increase.
• Analysts have set an average price target of $22.40 for Cellebrite DI, with several brokerages currently rating the stock as "Buy."

Canada Pension Plan Investment Board increased its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 100.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 161,671 shares of the company's stock after acquiring an additional 81,192 shares during the quarter. Canada Pension Plan Investment Board owned about 0.07% of Cellebrite DI worth $3,141,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. T. Rowe Price Investment Management Inc. purchased a new stake in Cellebrite DI during the 1st quarter valued at about $60,939,000. Invesco Ltd. increased its position in shares of Cellebrite DI by 122.1% in the 1st quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock valued at $64,043,000 after acquiring an additional 1,811,757 shares during the period. Handelsbanken Fonder AB boosted its stake in shares of Cellebrite DI by 749.9% during the 1st quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock worth $29,508,000 after acquiring an additional 1,340,000 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Cellebrite DI during the 1st quarter worth approximately $22,428,000. Finally, Nuveen LLC purchased a new stake in shares of Cellebrite DI during the 1st quarter worth $15,031,000. Institutional investors and hedge funds own 45.88% of the company's stock.

Cellebrite DI Price Performance

CLBT stock traded up $0.43 during midday trading on Monday, hitting $17.04. The stock had a trading volume of 1,690,911 shares, compared to its average volume of 1,695,169. Cellebrite DI Ltd. has a 52-week low of $13.10 and a 52-week high of $26.30. The business has a 50-day moving average of $15.03 and a two-hundred day moving average of $17.01. The firm has a market cap of $4.08 billion, a price-to-earnings ratio of -22.38, a price-to-earnings-growth ratio of 3.02 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm had revenue of $113.28 million during the quarter, compared to analysts' expectations of $112.33 million. During the same quarter in the previous year, the business earned $0.10 EPS. The company's quarterly revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered their price target on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, May 12th. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Finally, Lake Street Capital lowered their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a research report on Friday, August 15th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Cellebrite DI currently has a consensus rating of "Buy" and an average price target of $22.40.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.